I am a clinician scientist at Princess Margaret Cancer Centre and an assistant professor at the University of Toronto. Throughout my clinical career as a hematologist, I have treated numerous patients with lymphoid cancers and have witnessed many suffer from progressive or refractory disease. These experiences ignited a strong desire to pursue translational research aimed at improving patient survival through the development of more effective therapies.
The central focus of my research is to understand how interactions between tumor cells and the tumor microenvironment regulate cancer development and shape the tumor-educated microenvironment in lymphoid cancers, ultimately leading to biomarker discovery and novel therapeutic targets. I employ cutting-edge technologies, including single-cell sequencing, spatial transcriptomics, and proteomics assays, in conjunction with state-of-the-art preclinical in vitro and in vivo models. By integrating these approaches, my goal is to enhance patient outcomes through the establishment of precision medicine. To achieve this, I actively collaborate with leading researchers and clinicians worldwide, including clinical trial groups.
https://orcid.org/0000-0001-6782-8361